Plasmacytoid dendritic cell-mediated tumor antigen-specific cytotoxic CD8+ T-cell activation

The phrase "Tumor antigen-specific cytotoxic CD8+ T-cell activation via professional antigen presentation by plasmacytoid dendritic cells" describes a **cellular immunological process** rather than a discrete molecular target or receptor. In this context, **plasmacytoid dendritic cells (pDCs)** are a specialized subset of dendritic cells known primarily for their ability to produce large amounts of type I interferons in response to viral infection[3]. While conventional dendritic cells (cDCs) are well-established as professional antigen-presenting cells capable of efficiently priming both CD4+ and CD8+ T-cells, the role of pDCs in direct antigen presentation—especially for activating tumor-antigen specific cytotoxic CD8+ T-cells—is more limited and controversial[1][2]. Recent research indicates that while pDCs can capture and process antigens, they generally require cooperation with cDCs to effectively prime naive tumor-antigen specific cytotoxic CD8+ T-cells. This is achieved through the transfer of antigens from pDCs to cDC1-type conventional DCs—often mediated by exosomes derived from pDCs—which then perform the actual cross-presentation necessary for robust CTL responses[2]. Thus, this entry refers not to a single molecule or receptor but rather an intercellular mechanism critical in anti-tumor immunity. Because this is not a canonical molecular target but instead describes an immunological pathway/process involving multiple cell types and steps, it should be flagged as incorrect under standard target nomenclature conventions. The correct approach would be to refer specifically either to "Plasmacytoid dendritic cell" or relevant molecules involved in their function (e.g., MHC class I complex on DC subsets), depending on the intended focus[1][2][3].

Other names

Plasmacytoid dendritic cell antigen presentationpDC-mediated cross-primingpDC-induced CD8+ T-cell activation

Antigen cross-presentation to CD8+ T cells via MHC class I pathway (requires cooperation with conventional dendritic cells)